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Effects of nietolazone in man: Comparison with chiorothiazide.
The new diuretic agent, metolazone, was investigated to evaluate
its mode and sites of action in man. During sustained maximal
water diuresis metolazone produced a mean increment in sodium
excretion of 3.5% of filtered load, induced a phosphaturia
without an accompanying bicarbonate diuresis, and was mini-
mally kaliuretic or nonkaliuretic. Free water clearance decreased
and osmolal clearance increased almost equivalently (average:
2.6 and 3.4 mI/mm, respectively), and urine flow did not change
appreciably. Metolazone did not interfere with the reabsorption
of solute free water during hypertonic saline diuresis. Consistent
alterations of glomerular filtration rate, renal blood flow or
blood pressure were not observed. These results indicate that
metolazone exerts its major effect in the cortical diluting segment,
but that it also possesses a proximal site of action. At the dosages
utilized, its proximal effects do not appear to contribute signifi-
cantly to its diuretic action.
Chlorothiazide differed from metolazone in inhibiting carbonic
anhydrase, in producing a significant kaliuresis and in demon-
strating a greater proximal effect but a lesser inhibition of sodium
transport at the cortical diluting site. Additionally, the effect of
metolazone persisted at a time when that of chlorothiazide had
peaked and was declining rapidly.
Effet du metolazone chez l'homme: Comparaison avec le
chiorothiazide. Un nouvel agent diuretique, Ic métolazone a été
étudié afin d'en préciser Ic mode et les sites d'action chez l'homme.
Au cours d'une diurése aqueuse maximale prolongée, Ic métola-
zone provoque une augmentation moyenne de l'excrétion du
sodium d'environ 3.5% de Ia charge filtrée, il produit également
une phosphaturie sans diurése de bicarbonate associée. La kaliu-
rèse est minime ou absente.
La diminution de Ia clearance de l'eau libre est comparable
a l'augmentation de Ia clearance osmolaire (en moyenne, 2.6 et
3.4 ml par minute respectivement) et Ic debit urinaire n'est pas
change de facon appreciable. Le métolazone ne modifié pas Ia
reabsorption de l'eau libre au cours de Ia diurése saléc hyper-
tonique. Aucune modification appreciable de Ia filtration
glomerulaire, du debit sanguin renal ou de Ia pression artérielle
n'a eté notée. Ces résultats dCmontrent que le métolazone agit
principalement au niveau du segment de dilution cortical qu'il
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possède aussi un site d'action proximal. Aux doses employees,
ii ne semble pas que ses effets proximaux contribuent de
facon significative a son action diuretique.
Le chlorothiazide diffère du métolazone en ce qu'il bloque
l'anhydrase carbonique, produit une kaliurése significative de
même qu'un effet proximal plus grand et une inhibition moindre
du transport du sodium par le segment de dilution cortical. De
plus, l'effet du métolazone était persiste alors que celIa du
chlorothiazide a atteint son maximum et diminue rapidement.
Metolazone {2-methyl-3-(O-tolyl)-6-sulfamyl-7-chlo-
ro- 1 ,2,3,4-tetrahydro-4-quinazolinone} is a new orally
effective saluretic agent structurally related to the
sulfonamides and benzothiadiazine diuretics. Its phar-
machologic effects have been studied in experimental
animals where they have been thought to be similar
to those of hydrochlorothiazide but 8 to 10 times more
potent on a weight basis [1, 2]. It has been used
successfully in patients with edematous states and/or
hypertension [3]. The present study was undertaken
to delineate the site and mode of action of this agent
in normal man, and to assess its effectiveness in
varying dosages. Furthermore, because of reported
similarities between its chemical structure and the
pattern and magnitude of the diuresis as compared
to thiazides [1, 2], additional studies were undertaken
to define more strictly the similarities and differences
between these related compounds. The effects of
metolazone on the concentrating and diluting mecha-
nism, renal hen*odynamics, and the renal handling
of sodium, potassium, hydrogen ion, bicarbonate,
phosphate, and calcium were studied.
The results indicate that metolazone is a mild to
moderately potent natriuretic agent when administered
either orally or intravenously. Its onset of action is
prompt and the duration of natriuresis is prolonged.
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As noted with benzothiadiazine diuretics, this agent
also seemed to inhibit sodium transport in both the
proximal tubule and the cortical diluting segment of
the distal nephron. However, in marked contrast to
the former compounds, metolazone demonstrated no
carbonic anhydrase inhibitory activity. In addition,
potassium excretion either rose slightly, remained
constant or fell, whereas major kaliuresis resulted
from the administration of chiorothiazide.
Methods
Eighteen renal clearance studies were performed on
ten healthy male volunteers. All subjects gave negative
histories for organic disease and the presence of normal
renal function was assessed by determination of the
serum creatinine concentration and urinalysis. In-
formed written consent was obtained in all instances.
Water diuresis studies. Subjects were fasted over-
night, weighed prior to the start of the experiment, and
urine and serum were obtained for baseline studies.
A sustaining infusion of inulin and para-amino-
hippurate (PAH) in physiological saline solution was
begun at a rate of 1.0 ml/min and priming doses of
these substances were administered intravenously.
Each subject was then given 20 mI/kg of tap water
orally over a 30 minute period. The subjects remained
recumbent throughout the experiment, rising only to
void. Urine output was replaced with equal volumes
of tap water after each voiding. When steady state
maximal water diuresis had been achieved, as judged
by the collection of four to five clearance periods
during which urine flow varied by less than 5%,
a diuretic agent (metolazoneL or chlorothiazide2) was
administered. In two experiments metolazone was
given orally in a dosage of 2.5 mg. Intravenous meto-
lazone was infused over three to five minutes in doses
of 1 mg (three subjects), 2 mg (one subject), 3 mg
(one subject), and 5 mg (two subjects). Intravenous
chlorothiazide was administered in doses of 125 mg
(two subjects) and 500 mg (three subjects). Drug
action was monitored for two to four hours depending
upon the duration of the peak effect. The clearance of
inulin, PAH, sodium, potassium, calcium, phosphate,
and solute free water was assessed in all studies. The
Kindly supplied as Zaroxolyn®, Pennwalt Corp. Pharmaceuti-
cal Division, Rochester, N.Y., by Drs. Giovanni Costa and
Aldo Truant.
2 Generously provided by Drs. William H. Wilkinson and John
Baer, Merck Sharp and Dohme Institute for Research, West
Point, Pa., as Lyovac-Diuril®.
clearance of bicarbonate, serum and urinary pH, and
the urinary excretion of titratable acidity were meas-
ured in all but one of the intravenous drug studies.
Hydropenia experiments. The subjects were fasted
and deprived of water overnight and priming and
sustaining infusions of inulin and PAH were begun.
In addition, aqueous vasopressin was added to the
sustaining infusion (6 mU/mm). After 50 to 70 mi-
nutes, the subjects were asked to void and a constant
infusion of 3% sodium chloride solution was then
begun at 10 to 12 ml/min. Hypertonic saline alone was
infused continuously in three control studies, and
metolazone (1 mg i.v.) was given to three other subjects
during hypertonic saline diuresis after urine flow had
reached about 4 ml/min (and was continuing to in-
crease). Osmolal, inulin, PAH, sodium, and potassium
clearances were measured and the renal extraction of
solute free water (TCH,o) was calculated. Venous blood
for serum electrolytes, inulin and PAH was drawn at
the onset of steady state water diuresis or the beginning
of the solute diuresis (hydropenic studies), before each
experimental maneuver (administration of drug) and
every 30 to 45 minutes throughout the study. "Arte-
rialized" capillary blood was obtained via finger stick
for measurement of pH and P02.
Analytical methods. Inulin, PAH and phosphate were
determined in blood and urine by methods previously
described [4]. Blood for calcium was obtained under
oil, the serum was separated anaerobically and was
centrifuged under oil through a conical membrane
(Centriflo® centrifuge cones, Amicon Corp., Lexing-
ton, Mass.). Urinary and serum ultrafiltrable calcium
were then analyzed by atomic absorption spectrophoto-
metry (Perkin-Elmer Corp., Norwalk, Conn.). Sodium
and potassium in urine and serum were determined by
means of internal lithium standard flame photometry,
and osmolality was measured on an Advanced osmo-
meter. Blood pH and P02 were determined by the
Astrup technique (Radiometer, The London Company,
Westlake, Ohio) and bicarbonate concentration was
calculated from the Henderson-Hasselbalch equation
utilizing a pK of 6.10. Total urinary CO2 was analyzed
in duplicate by the manometric method of Van Slyke
and urinary pH was measured on a model PHM 27 pH
meter (The London Company). Titratable acidity was
analyzed with an automatic titration apparatus (model
TTT-1l, The London Company). Urinary bicarbonate
concentration was calculated from the values for
urinary pH and total CO2 utilizing a pK for urine of
6.13. The following formulae were employed:
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The clearance of solute free water (CH20) was deter-
mined from the relationship:
C0 =V— Cosm
where V = urine flow rate and Cøsm = the osmolal
clearance in mi/mm.
The rate of abstraction of solute free water from
the collecting duct (TCH20) was calculated as equal to
C0sm — V.
The percentages of filtered sodium, potassium,
calcium, and phosphate excreted into the urine were
determined as the ratio of the clearance of the re-
spective ion to that of inulin multiplied by 100. The
ratio CH2O/CIfl x 100 expresses the percentage of the
glomerular filtrate excreted as solute free water, and
V/C1,, x 100 represents the percent excretion of filtered
tubular fluid.
Standard methods of statistical analysis were
employed [5].
Results
Metolazone — Water diuresis studies. Table 1 con-
tains the results of nine acute clearance studies in
which the action of metolazone was superimposed
upon sustained water diuresis. The control observa-
tions (C) were obtained during maximal steady-state
water diuresis, and they are compared to those ob-
served during the presence of peak drug effect (P).
Each value represents the mean of two to four conse-
cutive clearance periods. The protocol of a represen-
tative study is shown in Table 2. An approximately
three-fold increase in absolute sodium excretion
(UNaV) developed in each study, while the percentage
of filtered sodium excreted (CNa/Clfl x 100) rose by a
mean value of 3.5% during the period of peak drug
action; both changes were significant (P<0.00l).
However, these changes were not accompanied by a
consistent kaliuresis irrespective of whether the drug
was given orally or intravenously. The absolute rate of
potassium excretion rose slightly in three subjects,
fell slightly to moderately in three, and remained
essentially unchanged in three; the percentage of
filtered potassium excreted rose slightly in five, fell
in two, and remained unchanged in two experiments.
In the study of subject J.D. (5.0 mg, i.v.), for example,
CNa/CIfl x 100 increased by 3.5% but there was no
change in either UKV or CK/CIfl x 100 (Table 1). In
eight of the nine studies, phosphaturia developed;
percentage phosphate excretion rose by a mean of
5.8% (P<0.0l) in all nine studies, and the range of
the increment was 1.6% to 10.5% in eight studies.
A modest increase in calcium excretion was also noted
in each case (mean increase of Cca/Cjn x 100: 2.2%);
whereas serum ultrafiltrable calcium varied randomly,
rising in two studies, falling in four, and remaining
essentially unchanged in two, with no significant differ-
ence noted in the mean value for the eight studies in
which it was determined (Table 1).
GFR varied inconsistently in these studies; it was
not necessarily depressed by larger doses of drug. In
fact, GFR rose in three studies (mean values:
106 8 mi/mm for control, and 103 11 mi/mm during
peak drug effect; P>0.60). Effective renal plasma flow
likewise demonstrated no consistent alteration.
Osmolal clearance (Cosm) rose in each study, with
a mean increase of 3.4 mI/mm. Since the small rise
in urine flow rate (V) (from 14.8 0.9 to 15.6 1.0 ml/
mm) was not statistically significant (P<0.10), the
increase in Csm can be seen to have occurred at the
expense of the excretion of CH20 (mean decline:
2.6m1/min; P<0.001). There was no significant differ-
ence between the control and peak diuretic-effect
periods when V was expressed as a percentage of GFR.
However, whereas CH2O/GFR demonstrated a signi-
ficant decline (P<0.05), it will be noted that in two
studies (J.D., 1.0mg; R.M., 5.0mg; Table 1) this
value actually rose (albeit by small amounts) and in
one study it was essentially unchanged (R.M., 1.0 mg).
The adequacy of the suppression of ADH during
water diuresis was verified by the fact that the control
urinary osmolality was always less than 80 mOsm/kg
(see Table 2).
Urinary pH and bicarbonate excretion were not
affected by metolazone as determined in six studies,
while titratable acidity increased slightly from 31.1
2.4 to 35.8 2.2 jtEq/min (P <0.01). Neither plasma
pH nor bicarbonate concentration were altered signif-
icantly. Metolazone produced a natriuresis after 6 to
23 minutes when given intravenously, and in 35 to
60 minutes following its oral administration. A sus-
tained plateau of drug effect was reached within 15 to
60 minutes after an intravenous dose and in 90 to
120 minutes when taken orally (Table 2, Fig. 1). Blood
pressure, which was monitored repeatedly throughout
each study, was not altered by the agent (see Table 2)
and no adverse side effects or untoward clinical re-
sponses were noted during the acute study or within
the subsequent 12 to 16 hours.
Chiorot/jiazide — Water diuresis studies. Table 3 sum-
marizes the data obtained when 125 mg (two studies)
or 500 mg (three studies) of chlorothiazide were ad-
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Table 1. Effect of metolazone on renal
Sub-
ject
Route Dose
mg
Period V
mi/mm
C1,,
mi/mm
CPAH
mi/mm
UN,,V
Eq/
mm
CNa/Cln
x 100
%
UKV
1zEq/
mm
CK/CIfl
x 100
%
UPV
umoles/
mm
CP/CIfl
x 100
%
T. D. p.o. 2.5 C
P
10.9
11.4
87
78
377
390
198
499
1.8
4.9
43.6
57.0
14.3
18.9
20.6
25.3
14.6
25.9
R. P. p.o. 2.5 C
P
15.3
14.6
90
101
452
450
235
597
1.9
4.4
71.0
54,0
21.3
13.9
13.6
19.2
15.0
17.1
J. D. i.v. 1.0 C
P
14.2
14.4
111
81
548
610
209
576
1.5
5.3
95.0
64.7
23
22.7
12.5
19.6
9.5
20.0
R. M. i.v. 1.0 C
P
13.6
14.9
109
88
541
401
68
503
0.5
4.5
40.1
44.6
11.5
16.3
13.7
21.3
8.9
14.2
B. R. i.v. 1.0 C
P
14.0
13.8
79
89
556
465
159
592
1.4
4.6
117.0
64.7
37.8
19.5
9.8
18.2
9.9
19.3
B. R. i.v. 2.0 C
P
13.3
13.8
109
102
396
488
182
674
1.2
4.8
49.7
55.3
13.4
15.5
2.5
13.0
2.2
11.9
R. M. i.v. 3.0 C
P
20.2
22.0
159
187
574
440
280
1064
1.2
3.9
40.4
66.2
6.4
10.2
18.1
20.9
10.1
8.1
J. D. i.v. 5.0 C
P
17.3
17.3
114
114
409
463
334
796
2.5
6.0
92.3
86.5
23.5
22.5
13.3
15.7
13.0
14.6
R. M. i.v, 5.0 C
P
14.7
18.0
106
91
551
435
166
851
1.1
6.9
29.4
36.1
8.4
11.5
33.6
32.9
21.1
25.3
Means
SaM
C
P
14.8
0.9
15.6
1.0
106
8
103
11
489
26
460
21
203
25
684
62
1.5
0.2
5.0
0.3
64.3
10.3
58.8
4.8
17.7
3.3
16.8
1.5
15.3
2.8
20.7
1.9
11.6
1.7
17.4
2.0b NS NS NS <0.001 <0.001 NS NS <0.005 <0.01
a Abbreviations: V = urine flow rate; C1,,, CPAH = clearance of inulin and p-aminohippurate; UNaV, UKV, U,V, U1103V, UTAV =
absolute excretion rates of sodium, potassium, phosphate, bicarbonate and titratable acidity; CNa/CIfl x 100, CK/CIfl x 100,
C/C1,, X 100, Ca/Cin x 100, CHCO3ICIfl x 100 = percentage of the filtered load of the respective ion which was excreted; SUFca=
serum ultrafiltrable calcium concentration; P, HCo3 = plasma levels of pH and bicarbonate concentration; N.D. = not deter-
mined; C, P = mean values for 2 to 4 consecutive clearance periods during control (C) and peak diuretic effect (P) phases of the
experiment, respectively.
Fig. 1. Time course of the effects of oral
and intravenous metolazone compared to
that of intravenously administered chloro-
thiazide on the percentage of filtered
sodium excreted (CNa/CIflX 100). Each
of the lines depicts a representative study
in which the administration of the agent
—120 —80 —40 0 40 80 120 160 200 240 was superimposed upon steady state
Time (mm) water diuresis (see text).
x
zU
125 mg chlorothiazidc i_v
5 mg metolazone iv. •--.
2.5 mg metolazone p.o. 0—0
hemodynamics, electrolyte and acid excretiona
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CCa/Cln
x 100
%
SUFa
mEq/liter
UPH UTAV
pEq/min
UHc03V
moles/
miii
CH(03/Cln
x 100
%
1pH 1HCO3
mmoles/
liter
CJJ20
mi/mm
Cøsm
mi/mm
V/Cm
X 100
%
CH20/CLfl
X 100
%
2.4
4.0
2.13
1.72
7.4
5.6
3.5
5.8
12.5
14.6
8.5
7.2
N.D.
N.D.
N.D.
N.D.
12.2
9.0
3.1
5.6
17.0
14.5
13.6
8.9
2.5
8.7
1.69
1.56
10.9
8.5
3.3
5.9
12.8
17.8
9.8
10.5
0.8
2.0
2.08
2.18
5.95
5.95
29.5
36.0
10.3
10.8
0.4
0.5
7.39
7.39
21.8
24.1
11.0
9.0
2.6
5.9
12.5
16.9
10.1
10.2
2.4
5.7
2.22
1.52
5.93
5.38
31.6
37.8
13.1
12.0
0.7
0.6
7.46
7.37
23.3
23.5
10.0
7.3
4.0
6.5
17.7
15.5
12.7
8.2
1.8
2.2
1.80
2.10
6.01
6.03
22.4
30.8
14.3
15.8
0.5
0.7
7.36
7.34
24.5
23.8
9.9
7.0
3.4
6.8
12.2
13.5
9.1
6.9
3.0
4.4
1.93
1.80
6.70
6.70
30.0
31.5
76.1
82.1
1.6
1.5
7.39
7.39
30.8
29.0
16.6
13.4
3.6
8.6
12.7
11.8
10.4
7.2
1.9
3.4
3.41
3.04
6.37
6.50
31.9
33.1
44.6
55.7
1.8
2.1
7.40
7.42
22.2
23.0
12.7
9.9
4.6
7.4
15.2
15.2
11.1
8.7
3.4
5.5
2.00
2.08
6.05
6.15
41.0
45.6
14.9
24.6
0.5
1:1
7.36
7.38
27.3
24.5
12.1
11.0
2.6
7.0
13.9
19.8
11.4
12.1
2.3
0.3
2.16
0.19
6.17
0.13
31.1
2.4
25.0
1.4
0.9
0.2
7.39
0.02
23.9
2.0
11.4
0.8
3.4
0.2
14.1
0.7
10.7
0.5
4.5
0.8
2.00
0.17
6.19
0.14
35.8
2.2
33.8
1.8
1.1
0.3
7.38
0.02
24.7
0.9
9.0
0.8
6.6
0.4
15.5
0.8
8.9
0.6
<0.02 NS NS <0.01 NS NS NS NS <0.001 <0.001 NS <0.05
b Value obtained employing Student's t test for non-independent variables; NS =not significant.
V/C111 x 100 and CHZO/CLII x 100 = the percentage of tubular fluid excreted and the percentage of the glomerular filtrate excreted as
solute free water, respectively.
ministered intravenously to subjects undergoing maxi-
mal sustained water diuresis. Several points of differ-
ence from and similarity to the metolazone experiments
are obvious:
The natriuresis after administration of 125 mg chlo-
rothiazide resembled that obtained with metolazone,
that is, CNa/CIfl x 100 increased by 3.8 to 4.4%. In
contrast, a somewhat greater sodium excretion was
obtained with 500 mg of chlorothiazide (increments of
6.9 to 7.4%).
Differences in the time course of the response to
these two agents are represented in Fig. 1. Both
intravenous metolazone and chlorothiazide acted
rapidly, but the effect of the latter drug soon abated
while that due to intravenous metolazone persisted
over the three hour period of observation. This
finding is confirmed by the values for UNaV in the
first, second and third hours following drug admini-
stration. Sodium excretion averaged 2,358 458,
2,725 507 and 2,408 309 p.Eq/h after metolazone,
values which did not differ from each other signifi-
cantly. For intravenous chlorothiazide, values of
2,741 644, 2,878 316, 1,992 373 tEq/h were ob-
tained; the value for the third hour differed signif-
icantly from that of the second hour (P<0.05). Oral
metolazone acted less rapidly but its effect on sodium
excretion was maintained up to four hours after ad-
ministration.
174 Steinmuller/ Puschett
Table 2. Representative experiment: Effect of the intravenous
Time
miii
V
mi/mu
C1 CPAH UNaV CNa/CIn UKV CKICIfl U,V C,/C1 UcaV
mi/mu mi/mm iiEq/min x 100 pEq/min x 100 pmoies/ x 100 pEq/min
% % mm %
—115 Obtain baseline blood and urine samples.
— 105 Begin sustaining infusion of inulin and PAH in physiological saline solution at 1 mI/mm.
— 102 Administer inulin and PAH priming doses.
— 100 to —80 Administration of 20 mI/kg water load.
0— 17 13.9 83 514 167 1.4 125 38.8 9.6 8.8 4.0
17— 35 14.6 76 679 161 1.5 117 38.5 10.4 11.2 4.8
35— 54 13.6 79 475 150 1.3 109 34.6 9.4 9.7 3.5
64— 68 Administration of 1 mg metolazone i.v.
54— 74 13.4 107 452 214 1.4 107 25.0 10.9 9.6 3.6
74—103 11.7 78 416 456 4.0 117 37.5 10.6 13.3 3.4
103—116 18.5 122 549 759 4.3 130 27.3 17,6 14.4 10.0
116—129 13.8 91 502 566 4.3 97 27.3 15.4 17.0 5.8
129—142 14.2 84 449 597 4.9 85 26.5 15.5 18.2 6.0
142—158 13.9 86 429 584 4.7 70 21.5 17.8 20.0 6.8
158—170 14.3 94 500 629 4.6 72 20.7 17.0 17.0 8.6
170—186 13.1 81 466 563 4.5 52 16.2 19.9 20.7 7.2
186-198 14.6 86 524 628 5.1 58 17.8 16.6 16.9 7.2
198—212 13.2 87 559 581 4.7 40 12.0 19.4 18.7 6.2
212—223 13.6 100 594 598 4.2 41 11.0 20.3 16.0 6.9
223—238 12.2 69 550 537 5.5 37 14.5 16.8 18.0 7.0
a Uosm = urinary osmolality; BP = brachia!
Table 3. Effect of chiorothiazide on renal
Subject Route Dose Period V C1 CPAH UNaV CNa/CIn UKV CK/CI UPV CP/CIfl
mg mi/mu mi/mm mi/mm pEq/min x 100 pEq/min x 100 pmoies/ x 100
% % miii %
D. M. iv. 125 C 11.0 75 347 151.7 1.4 55.2 17.5 11.1 11.8
P 14.7 84 393 609.4 5.2 99.2 30.5 22.2 22.5
T. D. i.v. 125 C 10.0 101 294 187.5 1.4 50.2 11.9 19.6 20.0
P 15.2 92 288 719.1 5.8 166.6 42.9 32.2 33.9
S. H. iv. 500 C 10.1 69 345 158.9 1.5 47.4 18.2 13.3 20.7
P 14.1 44 226 576.7 8.9 168.7 104.4 19.4 44.7
B. E. i.v. 500 C 17.2 97 478 206.7 1.6 34.4 9.6 15.2 12.7
P 22.6 93 481 1087.7 8.6 135.8 39.3 28.2 25.9
J. D. i.v. 500 C 19.0 108 347.8 2.4 180.9 42.7 10.1 9.4
P 24.2 98 227.9 9.3 249.5 68.3 28.4 26.9
Means C 13.5 90 366 210.5 1.7 73.6 20.0 13.9 14.9
SEM 1.9 8 39 35.7 0.2 27.0 5.9 1.7 2.3
P 18.2
2.2
82
10
347
56
844.2
132.1
7.6
0.9
163.9
24.8
57.1
13.4
26.1
2.3
30.8
3.9
P <0.001 NS NS <0.005 <0.005 <0.005 <0.05 <0.005 <0.005
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administration of metolazone during sustained water diuresisa
Ca/Cin SUFca Uosm CH2O CH20/CIfl UPH UTAV UHCO3V HCO3 BP
x 100 mEq/liter mOsm/kg mi/mm x 100 iiEq/min imoles/ x 100 mmoles/ mm Hg
mm % liter
2.2 2.25 81 9.9 12.0 6.00 28.5 14.6 0.8 23.3 100/70
2.9 2.22 80 10.5 13.8 5.90 33.6 12.9 0.7 23.3 110/70
2.0 2.21 78 9.7 12.3 5.90 32.6 11.7 0.6 23.3 100/70
1.5 2.21 90 9.1 8.5 5.90 32.2 — 23.3 110/70
1.9 2.26 134 6.1 7.8 5.90 29.2 — 22.8 104/70
3.6 2.30 131 9.8 8.1 5.90 46.2 20.2 0.7 23.4
2.8 2.31 131 7.3 8.0 5.90 35.9 12.1 0.6 23.4 104/70
3.4 2.05 134 7.4 8.7 5.90 35.5 12.2 0.6 23.4
4.5 1.76 132 7.4 8.6 5.85 37.3 10.6 0.5 23.4 106/70
6.3 1.46 132 7.6 8.0 5.85 39.3 13.3 0.6 23.5
6.3 1.33 133 6.9 8.0 5.80 36.7 23.5 110/70
6.8 1.22 130 7.8 9.1 5.80 40.9 23.6
6.4 1.12 131 7.0 8.1 5.80 37.0 23.7 120/70
5.0 1.39 132 7.2 7.1 5.75 38.3 23.8
6.0 1.68 129 6.5 9.5 23.9
blood pressure. Other abbreviations as in Table 1.
hemodynamics, electrolyte and acid excretion
Ca/Cin SUFca U11 UTAV U3V CHCO3/Clfl 'pH 1uco3 CH2O Cosm V/C1 C20/C1
x 100 mEq/liter iiEq/mmn imoles/ x 100 mmoles/ mi/mm mi/mm x 100 x 100
% miii liter % %
2.0 2.47 6.25 25.9 22.9 1.3 7.41 24.2 8.0 3.1 14.7 10.7
2.7 2.54 7.02 23.5 157.8 7.6 7.40 24.7 8.1 6.6 17.5 9.6
2.0 2.27 5.67 32.8 5.2 0.2 7.38 26.0 7.1 3.0 9.9 7.0
2.0 2.40 6.95 23.8 186.0 7.2 7.39 28.0 8.2 6.9 16.5 8.9
2.1 1.92 5.18 37.0 2.1 0.1 7.34 26.6 7.0 3.1 14.6 10.1
3.9 1.85 6.93 24.2 118.4 10.0 7.34 26.8 7.5 6.6 32.0 17.0
3.8 1.80 6.23 34.7 29.8 1.3 7.41 24.3 13.8 3.4 17.7 14.2
7.3 1.56 7.01 30.8 271.7 13.0 7.38 22.4 13.6 9.1 24.3 14.6
5.8 1.82 6.47 30.8 66.2 3.1 7.38 20.1 14.2 4.9 17.6 13.1
9.0 1.69 7.16 24.4 363.8 17.0 7.40 21.8 13.6 10.6 24.7 13.9
3.1 2.05 5.96 32.2 25.2 1.2 7.38 24.2 10.1 3.5 14.9 11.0
0.7 0.13 0.24 1.9 11.5 0.5 0.01 1.1 1.6 0.4 1.4 1.3
5.0 2.01 7.01 25.3 219.5 11.0 7.38 24.7 10.2 8.0 23.0 12.8
1.4 0.20 0.04 1.4 44.0 1.8 0.01 1.2 1.4 0.8 2.8 1.5
NS NS <0.01 <0.02 <0.005 <0.005 NS NS NS <0.001 <0.05 NS
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Fig. 2. Alterations in the percentage of filtered potassium ex-
creted (ACK/CIflx 100) evaluated at three levels of natriuresis as
measured by the increment in the percentage of sodium excreted
induced by metolazone (open circles) and chlorothiaide (closed
circles).
In contrast to metolazone, a major increase in
potassium excretion occurred with chiorothiazide
(Table 3). This difference in drug effect is depicted
graphically in Fig. 2 in which the ability of the two
agents to induce alterations in the percentage of fil-
tered potassium excreted into the urine is compared
at three levels of natriuresis as measured by the in-
crement in the percentage of filtered sodium excreted.
Only at a 4CNa/CIn x 100 of nearly 6% did a mild
kaliuresis result from metolazone. Furthermore, the
effect on potassium excretion was much less than that
effected by chiorothiazide at all levels of natriuresis.
Cblorothiazide produced an even more substantial
phosphaturia than metolazone with increases in per-
centage phosphate excretion of 10.3 and 13.9 % in the
low dose studies, and a mean increment of 15.9% for
all five studies (P<0.005). A mild calciuria also
occurred (means: 3.2 (C) -+ 5.0±1.4% (P)
for CCa/CIn x 100), which was not quite significant
statistically (F> 0.05). Serum ultrafiltrable calcium
concentration showed no essential change.
As opposed to the data for CH2O obtained for meto-
lazone (Table 1) the absolute value for this parameter
did not decline when chlorothiazide was studied nor
T was a consistent fall demonstrated when CH20 wasj expressed as a percentage of the glomerular filtration
T rate (Table 3). In fact, in one study (S.H., Table 3)
1 C2o/C1fl x 100 actually rose quite substantially. In
addition, chlorothiazide always induced an increase
in V (mean values rose from 13.5± 1.9 to 18.2±
2.2 mi/mm; P<0.OOl) and the percentage of filtered
water excreted (mean increment in V/CIa x 100:
8.0%; P<0.05).
Hydropenia studies. The ability of metolazone to
interfere with the reabsorption of solute free water
(Tc1120) was evaluated by superimposing its admini-
stration on the intravenous infusion of hypertonic
(3%) saline solution. In addition to the persistent
stimulus for antidiuretic hormone elaboration pro-
vided by overnight water deprivation, exogenous
vasopressin was continuously provided throughout
the study in supraphysiologic dosage. In Fig. 3 are
shown the results in three normal subjects given
hypertonic saline alone (open symbols), and in -three
additional studies in which the administration of
1 mg of metolazone intravenously was superimposed
upon the saline infusion (closed symbols). Following
hypertonic saline infusion alone, continuously in-
creasing rates of Cosm were accompanied by values for
TcH2O which continued to rise in two subjects and
began to level off in the other as C0sm increased up to
28 to 30 ml/min. The superimposition of metolazone
on the saline infusion did not alter the curve of rising
TCH2O as Csm continued to increase over ranges
comparable to those obtained in the control subjects
(Fig. 3), thus demonstrating the absence of an effect
of metolazone on free water reabsorption at this
25
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Further distinctions between the effects of the two
drugs are obvious from a review of the data on acid
--- excretion with chlorothiazide (Table 3). Whereas
metolazone produced no change in urinary pH or
J bicarbonate excretion and a slight but significant rise
+ T in titratable acidity (Tables 1 and 2), chlorothiazideinduced a profound increment in urinary pH (mean
increase: 1.05 pH units; P<0.01), in absolute bi-
I I I carbonate excretion (a nine-fold increase for the five
2 3 4 5 6
studies), and in the percentage of filtered bicarbonate
appearing in the urine (means: 1.3 0.5 % and
13.2 1.7% in the control and peak drug effect phases,
respectively), whereas titratable acidity fell from
32.2 1.9 to 25.3 1.4 iEq/min (P =0.02). These
alterations in urinary acid excretion occurred without
noticeable change in plasma pH or bicarbonate con-
centration (Table 3).
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dosage level. Potassium excretion increased pan passu
with rising sodium excretion in all three control
studies, as was the case in two of the three subjects
given metolazone, while in one experiment, it declined
substantially.
Discussion
Investigations of the sites and modes of action of
diuretic agents utilizing clearance methodology have
been directed toward establishing the ability of the
drug to alter the normal mechanisms of urinary con-
centration and dilution [6, 7] and to inhibit the
reabsorption of ions such as potassium, phosphate and
bicarbonate which have fairly well localized transport
loci within the nephron [4, 7]. In the experimental
animal and in man, metolazone has been noted to
interfere with urinary dilution [1, 8], and to cause
either no change or an improvement in urinary con-
centrating ability in the dog [1]. Furthermore, con-
sistent effects on urinary pH or potassium excretion
have not been demonstrated in experimental animals,
and the institution of acidosis or alkalosis did not
appear to interfere with the saluretic effect [1]. The
present studies were undertaken to more carefully
delineate the site and mechanism of action of this drug
as well as to establish its natriuretic potency in com-
parison to other agents.
When the secretion of antidiuretic hormone (ADH)
has been maximally suppressed, urinary dilution occurs
at two sites in the nephron: in the ascending limb of
Henle's loop in the renal medulla, and at a second
site functionally located in the renal cortex, early in
the distal convoluted tubule [9—i 1]. The ability of the
kidney to dilute the tubular contents can be quantified
by determining the amount of tubular fluid freed of
solute per minute (CH20). During maximal water
diuresis the urinary flow rate can be considered to
reflect a reasonable approximation of end-proximal
tubular volume flow [12] albeit it is recognized that
even in this circumstance, some water reabsorption
into the medulla occurs from the descending limb and
that ADH-independent back-diffusion of water occurs
from the collecting duct even at high urine flow rates
[13]. During antidiuresis, only the ascending limb
participates in urinary concentration by virtue of
its ability to pump sodium into the medulla, a process
which is requisite for the maintenance of a hypertonic
medullary interstitium, thus serving to produce the
osmotic force for the extraction of solute free water
from the collecting duct (TCH20). Therefore, a drug
which interferes with both urinary dilution and con-
centration must have a major inhibitory effect on
sodium transport in the ascending limb, wherever else
it may act, whereas one which disturbs only dilution
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Fig. 3. The abstraction of solute free
water (T°2o) plotted as a function of
increasing amounts of solute cleared
(Cosm) during the infusion of hypertonic
saline solution, alone, to three normal
subjects (open symbols), compared to the
values obtained in three additional sub-
jects to whom 1 mg of metolazone was
administered intravenously (closed sym-
bols) at a point in their respective studies
indicated by the arrows.
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(especially if C1120 is not greatly reduced) most likely
is active solely at the cortical diluting site. Additionally,
agents which have a major proximal effect would be
expected to enhance both C20 and Tc1120 by delivering
increased amounts of isotonic proximal tubular con-
tents to more distal reabsorptive sites.
Although it is possible that, had the drug been
given at higher dosage, TcH2O might have changed,
nevertheless, the fact that metolazone did not alter
Tc1120 during hypertonic saline diuresis, but did depress
CH20 by approximately 23%, strongly suggests that
the drug inhibits sodium transport at the cortical
diluting site. Additional evidence in favor of this
postulate is provided by an evaluation of the effect
of metolazone on V and Cosm in relation to that on
CH2O. Since, during maximal suppression of ADH,
the cortical diluting site is already essentially imperme-
able to water, an agent which inhibits sodium trans-
port at this site would not be expected to produce any
substantial change in tubular volume, and therefore
no alteration in urine flow should result. However,
since C1120 is a measure of sodium reabsorption at
this site, the extent to which C1120 is depressed should
be reflected in a reciprocal rise in C0sm. In the metola-
zone investigations herein reported, there was no
significant alteration in V, whereas C1120 declined by
almost the same amount as Cøsm rose. Furthermore,
because GFR showed an insignificant change, the
relation of V, C1120 and C0 to each other was un-
altered when the mean values obtained for these
parameters were expressed as percentages of the
glomerular filtration rate.
Unlike metolazone, chlorothiazide induced a signif-
icant increase in V with no change in CR20, an obser-
vation similar to that reported by Heinemann, DeMar-
tini and Laragh, in human subjects [14]. However,
the administration of larger doses of the drug to dogs
by Parley, Kahn and Orloff [11] and by Suki, Rector
and Seldin [15] resulted in significant depressions in
CH2O. Although not performed in this study, evalua-
tions of Tc1120 in the experimental animal have demon-
strated a lack of interference with the concentrating
mechanism by this agent [11, 15]. In addition, there
was, in every chlorothiazide study, an increase in the
percentage of filtered water which was excreted and
in two of five subjects, the percentage of filtered
sodium reabsorbed by the diluting sites (as measured
by CH,O/CIfl x 100) actually rose. In view of these
observations, the action of the drug seems best
summarized as representing a combined effect at two
sites, that is, an inhibition of proximal transport
matched by an equivalent effect on sodium reabsorp-
tion at the cortical diluting site. As a corollary to these
findings, it seems reasonable to conclude also, since
an equivalent natriuresis occurred with 125 mg of
chlorothiazide and three to five mg of metolazone,
that metolazone produced a more substantial effect
at the cortical diluting segment than did chlorothiazide.
Whereas sodium and calcium reabsorption occur
throughout the nephron [10, 16-18], the transport of
filtered phosphate appears to be essentially limited to
its reabsorption in the proximal convolution [19—21].
The demonstration that metolazone produced a
phosphaturia in eight of nine studies provides additio-
nal evidence for a proximal action of the drug. The
phosphaturia which accompanied the diuretic action
of chiorothiazide was greater than that induced by
metolazone and has recently been described also by
Eknoyan, Suki and Martinez-Maldonado [22].
Previous suggestions of a transport linkage between
sodium and phosphate based on clearance data [23—25],
have been confirmed by micropuncture investigations
of the proximal tubular handling of these two ions
[26, 27]. It therefore seems reasonable to postulate
that the action of metolazone to inhibit proximal
phosphate transport must also have included the
delivery of increased amounts of sodium and tubular
fluid to the distal nephron. However, the fact that
urinary flow rate did not increase in these studies
suggests that the magnitude of this effect was not
great, and that the tubular water delivered distally may
have diffused into the renal medulla from the de-
scending limb or the collecting duct. Furthermore, the
presumed small increment in sodium delivered down-
stream could account for the fact that Cosm rose by
slightly more than C1120 fell, although it is also possible
that some of this sodium may have been reabsorbed
distally. Reasoning similarly as to the action of chioro-
thiazide, its more potent phosphaturic action than
that of metolazone provides additional evidence in
support of the view, based on the V and C1120 data,
that the drug acts both proximally and at the cortical
diluting site. While this conclusion regarding proximal
effects of chiorothiazide is compatible with the C1120
data reported by Heinemann et al [14], it should be
pointed out that a proximal effect of hydrochloro-
thiazide has not yet been demonstrated in micro-
puncture studies [28], possibly because of the lack of
replacement of urinary losses and/or due to alterations
in GFR [29],
There are two possible explanations for the phos-
phaturia which developed following metolazone ad-
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ministration. Carbonic anhydrase inhibition has regu-
larly been shown to result in a phosphaturia as well as
a bicarbonate diuresis [4, 30, 31]. Since metolazone
shares with chlorothiazide, I urosemide and acetazol-
amide the presence of an unsubstituted —SO2NH2
group, the chemical structure which has been demon-
strated by Maren and his colleagues to be requisite for
carbonic anhydrase inhibitory action [32], we fully
expected that metolazone would prove to be an
inhibitor of this enzyme in vivo. However, the drug
did not induce any alteration in urinary pH or bi-
carbonate excretion. Therefore, the metolazone-in-
duced phosphaturia was most likely due to the in-
hibition of a sodium transport mechanism linked to
that of phosphate in the proximal tubule [26,21].
The available evidence indicates that filtered potas-
sium is completely reabsorbed proximally, so that
excretion of this ion into the urine under normal
circumstances must represent distal secretion [33].
Furthermore, potassium and hydrogen are exchanged
for sodium in the late distal convolution (and perhaps
also in the collecting duct) at sites sensitive to the
action of aldosterone [34]. Therefore, agents which in-
hibit sodium transport proximal to these Nat—H —K
exchange sites would be expected to provide an in-
creased opportunity for kaliuresis, an observation
which no doubt accounts for the hypokalemia in-
duced by a number of diuretic agents [6]. Despite a
natriuresis amounting to up to nearly 6% of the
filtered load of sodium, metolazone produced little if
any kaliuresis, whereas a rise in titratable acidity was
noted. The increase in titratable acidity observed is
what one would expect from the increased presentation
of sodium to a tubular site capable of exchanging
sodium for hydrogen ions [34]. At least three possi-
bilities exist which could explain the minimal kaliuresis
induced by metolazone and the disparity observed in
its action on potassium and hydrogen excretion com-
pared to that of chlorothiazide. First, it is well known
that carbonic anhydrase inhibitors produce significant
kaliuresis with the proposed mechanism including the
preferential exchange of potassium for sodium in
renal tubular cells whose ability to secrete hydrogen
ion into the lumen has been impaired [35]. Thus meto-
lazone might have a proportionately weaker effect on
potassium excretion than chlorothiazide because it
does not inhibit carbonic anhydrase. However, it
seems unlikely that this is the sole explanation since
an agent such as ethacrynic acid, which, like metola-
zone is not a carbonic anhydrase inhibitor [4], induces
a substantially greater kaliuresis than metolazone at
comparable levels of natriuresis to those induced by
the latter drug in this investigation ([7], and Puschett,
J. B., and Goldberg, M.: unpublished observations).
Secondly, it is possible that the relatively minor
effects on potassium excretion observed with metola-
zone were the result of the fact that this drug has an
insubstantial proximal action, and that the greater
effect of chlorothiazide at the latter nephron site
resulted in the downstream delivery of larger amounts
of potassium from the proximal tubule, which was not
reabsorbed distally. While it seems reasonable that
such a course of events may well have added to the
kaliuretic effect of chlorothiazide and could magnify
the disparity in potassium excretion produced by the
two drugs, this hypothesis still does not provide a
suitable explanation for the minimal kaliuresis ob-
served with metolazone.
Finally, it is possible that metolazone may suppress
potassium secretion directly. Certainly the pattern of
the diuresis, with reduced potassium excretion as
compared to control levels at low rates of natriuresis,
and minimal kaliuresis at somewhat higher rates of
sodium excretion (see Fig. 2), is compatible with this
thesis. However, the drug was not administered to
potassium-loaded subjects, nor is there data in this
report which describes the effect of metolazone on
potassium excretion in edematous patients in whom
secondary hyperaldosteronism exists. In addition, the
potassium excretion data obtained after metolazone
administration during hypertonic saline diuresis proved
to be inconclusive. Therefore, it is not possible to
differentiate on the basis of the experimental observa-
tions reported here which of the mechanisms just
discussed contribute to an adequate explanation of
the acute effects of the drug on potassium transport.
Nevertheless, whatever the means by which this
action of metolazone becomes manifest, the salient
observation to be made is that at equivalent degrees
of natriuresis, this agent is much less kaliuretic than
is chlorothiazide. Whether or not metolazone will
prove to be relatively "potassium-sparing" in clinical
usage cannot be predicted from these data.
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